942123-43-5

942123-43-5 structure

Name: Inarigivir soproxil
Chemical Name: inarigivir soproxil
CAS Number: 942123-43-5
Molecular Formula: C₂₅H₃₄N₇O₁₃PS
Molecular Weight: 703.615
Catalog: Signaling Pathways Anti-infection HCV
Create Date: 2018-10-17 16:58:56
Modify Date: 2024-01-10 08:29:26
Inarigivir soproxil is an agonist of innate immunity and shows potent antiviral activity against resistant hepatitis C virus (HCV) variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems.

Name	inarigivir soproxil
Synonyms	inarigivir soproxil [({[(2R,3S,5R)-5-(6-Amino-9H-purin-9-yl)-3-hydroxytetrahydro-2-furanyl]methoxy}{[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-2-(hydroxymethyl)-4-methoxytetrahydro-3-furanyl]oxy}phosphoryl)sulfanyl]methyl isopropyl carbonate 365052M0DK

Description	Inarigivir soproxil is an agonist of innate immunity and shows potent antiviral activity against resistant hepatitis C virus (HCV) variants, with EC50s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems.
Related Catalog	Signaling Pathways >> Anti-infection >> HCV Research Areas >> Infection
Target	EC50: 2.2/1.0 μM (HCV 1a/1b)[1].
In Vitro	Inarigivir soproxil (SB 9200) is an oral modulator of innate immunity that is believed to act via the activation of the RIG-I and NOD2 pathways. SB 9200 has broad-spectrum antiviral activity against RNA viruses including hepatitis C virus (HCV), norovirus, respiratory syncytial virus and influenza and has demonstrated activity against hepatitis B virus (HBV). Inarigivir soproxil is shown to inhibit HCV replication and the range of inhibition is comparable between genotypes 1a and 1b. Inarigivir soproxil demonstrates pan-genotypic antiviral activity against HCV. Inarigivir soproxil is active against DAA-resistant HCV variants[1].
References	[1]. Jones M, ET AL. SB 9200, a novel agonist of innate immunity, shows potent antiviral activity against resistant HCV variants. J Med Virol. 2017 Sep;89(9):1620-1628.